R. L. Siegel, K. D. Miller, and A. Jemal, Cancer statistics, CA Cancer J Clin, vol.69, pp.7-34, 2019.

A. F. Hezel, V. Deshpande, and A. X. Zhu, Genetics of biliary tract cancers and emerging targeted therapies, J Clin Oncol, vol.28, pp.3531-3540, 2010.

N. Razumilava and G. J. Gores, Cholangiocarcinoma. Lancet, vol.383, issue.13, pp.61903-61903, 2014.

J. Bridgewater, Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma, J Hepatol, vol.60, pp.1268-1289, 2014.

J. N. Primrose, Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study, Lancet Oncol, vol.20, issue.18, p.30915, 2019.

J. Edeline, Gemcitabine and Oxaliplatin chemotherapy or surveillance in resected biliary tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study, J Clin Oncol, vol.37, pp.658-667, 2019.

A. Mahipal, S. H. Tella, A. Kommalapati, D. Anaya, and R. Kim, FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma, Cancer Treat Rev, vol.78, pp.1-7, 2019.

J. Valle, Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer, N Engl J Med, vol.362, pp.1273-1281, 2010.

J. Bridgewater, Quality of life, long-term survivors and long-term outcome from the ABC-02 study, Br J Cancer, vol.114, pp.965-971, 2016.

T. Okusaka, Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer, Cancer Sci, vol.102, pp.425-431, 2011.

T. Conroy, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, vol.364, pp.1817-1825, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00598658

V. Hoff and D. D. , Increased survival in pancreatic cancer with nabpaclitaxel plus gemcitabine, N Engl J Med, vol.369, pp.1691-1703, 2013.

A. Ulusakarya, Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma. Medicine (Baltimore) 98:e15341, 2019.

R. Filippi, Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives, Expert Opin Pharmacother, vol.20, pp.2121-2137, 2019.

J. M. Phelip, Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: study protocol for a randomized controlled multicenter phase II/III study, Dig Liver Dis, vol.51, pp.318-320, 2019.
URL : https://hal.archives-ouvertes.fr/hal-01980019

L. Perkhofer, Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer -the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study, BMC Cancer, vol.19, p.990, 2019.

A. Belkouz, Efficacy and safety of FOLFIRINOX in advanced biliary tract cancer after failure of gemcitabine plus cisplatin: a phase II trial, J Clin Oncol, vol.37, pp.4086-4086, 2019.

T. Kus, G. Aktas, M. E. Kalender, A. Sevinc, and C. Camci, Comparison of FOLFIRINOX chemotherapy with other regimens in patients with biliary tract cancers: a retrospective study, J Gastrointest Cancer, vol.48, pp.170-175, 2017.

D. Boakye, Impact of comorbidity and frailty on prognosis in colorectal cancer patients: a systematic review and meta-analysis, Cancer Treat Rev, vol.64, pp.30-39, 2018.

K. Jordan, Supportive treatments for patients with Cancer, Dtsch Arztebl Int, vol.114, pp.481-488, 2017.

E. Alabraba, Increased multimodality treatment options has improved survival for hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged, Eur J Surg Oncol, vol.45, pp.1660-1667, 2019.

A. Trotti, CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment, Semin Radiat Oncol, vol.13, issue.03, pp.31-37, 2003.

P. Therasse, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, vol.92, pp.205-216, 2000.

J. W. Valle, Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials, Ann Oncol, vol.25, pp.391-398, 2014.

D. Malka, Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, noncomparative phase 2 trial, Lancet Oncol, vol.15, pp.70212-70220, 2014.

A. J. Scott and R. T. Shroff, Moving the needle forward with Locoregional treatment in Unresectable Cholangiocarcinoma-the jury is still out, JAMA Oncol, 2019.

J. Edeline, Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic Cholangiocarcinoma: a phase 2 clinical trial, JAMA Oncol, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02364095

A. Cercek, Assessment of hepatic arterial infusion of Floxuridine in combination with systemic gemcitabine and Oxaliplatin in patients with Unresectable intrahepatic Cholangiocarcinoma: a phase 2 clinical trial, JAMA Oncol, 2019.

R. T. Shroff, Gemcitabine, Cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial, JAMA Oncol, vol.5, pp.824-830, 2019.

J. Peron, An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma, Oncotarget, vol.7, pp.82953-82960, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02053624

V. De-jesus, Retrospective comparison of the efficacy and the toxicity of standard and modified FOLFIRINOX regimens in patients with metastatic pancreatic adenocarcinoma, J Gastrointest Oncol, vol.9, pp.694-707, 2018.

H. Kang, Comparison of efficacy and safety between standarddose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer, World J Gastrointest Oncol, vol.10, pp.421-430, 2018.

L. J. Havrilesky, M. Reiner, P. K. Morrow, H. Watson, and J. Crawford, A review of relative dose intensity and survival in patients with metastatic solid tumors, Crit Rev Oncol Hematol, vol.93, pp.203-210, 2015.

S. Kobayashi, Influence of initial dose intensity on efficacy of FOLFIRINOX in patients with advanced pancreatic cancer, Oncotarget, vol.10, pp.1775-1784, 2019.

J. C. Lee, Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: using cumulative relative dose intensity, Eur J Cancer, vol.76, pp.125-133, 2017.

R. Adam, Hepatic resection after down-staging of unresectable hepatic colorectal metastases, Surg Oncol Clin N Am, vol.12, pp.85-91, 2003.

R. Adam and Y. Kitano, Multidisciplinary approach of liver metastases from colorectal cancer, Ann Gastroenterol Surg, vol.3, pp.50-56, 2019.

N. U. Tariq, M. G. Mcnamara, and J. W. Valle, Biliary tract cancers: current knowledge, clinical candidates and future challenges, Cancer Manag Res, vol.11, pp.2623-2642, 2019.

W. Song, A nomogram to predict overall survival for biliary tract cancer, Cancer Manag Res, vol.10, pp.1535-1541, 2018.

I. T. Konstantinidis, Unresectable intrahepatic cholangiocarcinoma: systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone, Cancer, vol.122, pp.758-765, 2016.

F. A. Levi, Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV, Ann Oncol, vol.27, pp.267-274, 2016.

C. Yoo, Multicenter phase II study of oxaliplatin, irinotecan, and S-1 as first-line treatment for patients with recurrent or metastatic biliary tract cancer, Cancer Res Treat, vol.50, pp.1324-1330, 2018.

, Publisher's Note

, Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations